NCT02567682View on ClinicalTrials.gov

Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Sickle Cell Disease
Interventions
DRUG

GBT440

GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam

Trial Locations (1)

78209

ICON Early Phase Services, LLC Clinical Research Unit, San Antonio

Sponsors
All Listed Sponsors
lead

Global Blood Therapeutics

INDUSTRY

NCT02567682 - Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects | Biotech Hunter | Biotech Hunter